New cocktail targets brain lymphoma: early trial launches

NCT ID NCT06730542

Recruiting now Disease control Sponsor: Juan P. Alderuccio, MD Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether adding the targeted drug zanubrutinib to a standard chemotherapy regimen (Pola-R-CHP plus high-dose methotrexate) is safe for people with large B-cell lymphoma that has spread to the central nervous system (brain or spinal cord). About 20 adults will take part. The main goal is to check for serious side effects; researchers will also watch whether tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Zanubrutinib (a targeted cancer drug taken as capsules) combined with standard chemotherapy drugs (Polatuzumab Vedotin, Rituximab, Cyclophosphamide, and high-dose Methotrexate)
What this could lead to: If this combination is safe and effective, it could offer a new treatment option for patients with lymphoma that has spread to the brain or spinal cord.
What could go wrong: This is a very early (Phase 1) trial with only 20 people, so the main goal is safety, not proof of benefit. The drug combination may cause serious side effects, and it is not yet known if it will improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CNS LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CNS LYMPHOMA

Contacts and locations

Locations

University of Miami
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.